Last $0.28 USD
Change Today -0.005 / -1.79%
Volume 6.3K
AOLS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

aeolus pharmaceuticals inc (AOLS) Key Developments

Aeolus Pharmaceuticals, Inc. Announces Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure

Aeolus Pharmaceuticals Inc. announced the publication of data from animal model studies demonstrating the efficacy of AEOL 10150 when used to treat skin lesions from the sulfur mustard gas analog CEES. The key findings described in the publication include: Treatment of mice with AEOL 10150 resulted in over 50%(p < 0.05) reversal of CEES-induced skin bi-fold and epidermal thickness, myeloperoxidase activity, and DNA oxidation in mouse skin; Treatment of mouse epidermal JB6 and human HaCaT cells with AEOL 10150 (50 uM) 1 hour post-CEES exposure resulted in significant (p < 0.05) reversal of CEES-induced decreases in both cell viability and DNA synthesis; AEOL 10150 treatment 1 hour after CEES exposure attenuated CEES-induced DNA damage in mouse epidermal JB6 and human HaCaT cells; Cytoplasmic and mitochondrial reactive oxygen species measurements showed that AEOL 10150 treatment drastically ameliorated the CEES-induced oxidative stress in both JB6 and HaCaT cells.

Aeolus Pharmaceuticals Inc. Presents at LD MICRO 4th Annual Micro-Cap Invitational, Jun-04-2014 04:30 PM

Aeolus Pharmaceuticals Inc. Presents at LD MICRO 4th Annual Micro-Cap Invitational, Jun-04-2014 04:30 PM. Venue: Luxe Sunset Bel Air, 11461 Sunset Boulevard, Los Angeles, CA 90049, United States. Speakers: David C. Cavalier, Chairman of The Board, Chief Financial Officer, Principal Accounting Officer and Secretary.

Aeolus Pharmaceuticals Inc., Q2 2014 Earnings Call, May 19, 2014

Aeolus Pharmaceuticals Inc., Q2 2014 Earnings Call, May 19, 2014

Aeolus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2014

Aeolus Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2014. The company reported net loss of $437,000. This compares to net loss of $5,782,000, including a non-cash adjustment for increases in valuation of warrants of $5,020,000, or $0.06 per basic and diluted share, for the three months ended March 31, 2013. Contract revenue was $1,438,000, against $859,000 for the three months ended March 31, 2013. The revenue is from the contract with BARDA announced on February 11, 2011. Higher revenue in 2014 reflects both the timing of the initiation of program items as well as revenue recognition under accounting rules. Loss from operations was $437,000 against $762,000 last year. For the six months ended March 31, 2014, the company reported net loss of $1,132,000 or $0.01 per basic and diluted share. This compares to net loss of $1,755,000, including a non-cash adjustment for increases in valuation of warrants of $510,000 or $0.03 per basic and diluted share for the six months ended March 31, 2013. Contract revenue was $2,231,000, against $2,201,000 last year. Loss from operations was $1,132,000 against $1,245,000 last year. Net cash used in operating activities was $349,000 against $1,913,000 last year.

Aeolus Pharmaceuticals Inc., Annual General Meeting, Apr 21, 2014

Aeolus Pharmaceuticals Inc., Annual General Meeting, Apr 21, 2014. Agenda: To discuss re-electing seven directors of the company; to consider the ratifying the selection by the Audit Committee of the Board of Directors of Grant Thornton LLP as the company's independent registered public accounting firm; to consider the compensation paid to the named executive officers; and to consider the approving an advisory vote every three years concerning the frequency of the executive compensation advisory vote.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AOLS:US $0.28 USD -0.005

AOLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AOLS.
View Industry Companies
 

Industry Analysis

AOLS

Industry Average

Valuation AOLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.3x
Price/Book 1,160.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEOLUS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.